Philip J. Koo, MD, presented “Point-Counterpoint: Will Conventional Imaging Become Obsolete? – Pro” during the 30th Annual Perspectives in Urology: Point-Counterpoint, on March 10, 2023, at Humphreys Half Moon Inn, San Diego, California.
How to cite: Koo, Philip J. “Point-Counterpoint: Will Conventional Imaging Become Obsolete? – Con.” March 10, 2023. Accessed Nov 2024. https://grandroundsinurology.com/point-counterpoint-will-conventional-imaging-become-obsolete-pro/
Point-Counterpoint: Will Conventional Imaging Become Obsolete? – Pro – Summary
Philip J. Koo, MD, delves into the ProPSMA Study, shedding light on the remarkable superiority of PSMA PET over conventional imaging in detecting prostate cancer. The study’s findings showcased an impressive treatment impact of 92% for PSMA PET, surpassing the 65% achieved by conventional imaging, while also demonstrating fewer uncertain results.
Dr. Koo emphasizes that PSMA PET is recommended for patients classified as unfavorable, intermediate, high, and very high-risk, while low or intermediate-risk patients do not require conventional imaging. Moreover, the recognition of PSMA PET’s performance in response assessment is steadily growing, signaling its potential as a reliable and accurate tool in evaluating treatment effectiveness.
The increasing utilization of PSMA PET in other countries hints at an imminent shift in the global landscape of prostate cancer imaging. With ongoing advancements and cost reductions, the wider accessibility and affordability of PSMA PET hold the promise of revolutionizing the field and improving patient outcomes on a global scale.
This lecture is part of a Point-Counterpoint debate. Its opposing lecture is “Point-Counterpoint: Will Conventional Imaging Become Obsolete? – Con.”
About the 30th Annual Perspectives in Urology: Point Counterpoint conference: Presented by Program Chair and Grand Rounds in Urology Editor-in-Chief E. David Crawford, MD, this conference brought together leading experts in urology, medical oncology, and radiation oncology to discuss and debate the latest topics in genitourinary cancers, primarily prostate cancer and bladder cancer. This interactive conference offered topical lectures, pro/con debates, interesting-case presentations, interactive panel discussions, and interactive audience and faculty networking.
ABOUT THE AUTHOR
Phillip J. Koo, MD, is the Chief of Diagnostic Imaging at the Banner MD Anderson Cancer Center in Phoenix, Arizona. Prior to this, he was Chief of Nuclear Medicine and Associate Professor of Radiology at the University of Colorado School of Medicine in Aurora, Colorado. He completed his fellowship at the Harvard Medical School Joint Program in Nuclear Medicine in Boston, Massachusetts. Dr. Koo is a diplomate of both the American Board of Radiology (ABR) and American Board of Nuclear Medicine(ABNM).
